Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2015 ASCO Annual Meeting

29 May - 2 Jun 2015
McCormick Place, Chicago, United States of America
Exciting new developments in proton therapy treatments
Dr Hernán Cortés-Funes - HC Marbella, Marbella, Spain
Exciting new developments in proton therapy treatments ( Dr Hernán Cortés-Funes - HC Marbella, Marbella, Spain )
16 Jun 2015
PDL1 expression in thymic tumours
Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA
PDL1 expression in thymic tumours ( Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA )
16 Jun 2015
Exciting update on the Repurposing Drugs in Oncology (ReDO) project
Dr Gauthier Bouche - Anticancer Fund, Strombeek-Bever, Belgium
Exciting update on the Repurposing Drugs in Oncology (ReDO) project ( Dr Gauthier Bouche - Anticancer Fund, Strombeek-Bever, Belgium )
15 Jun 2015
PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
Dr Emiliano Calvo - START Madrid, Madrid, Spain
PM1183 plus doxorubicin shows interesting activity in small cell lung cancer ( Dr Emiliano Calvo - START Madrid, Madrid, Spain )
12 Jun 2015
Round-up of the latest research on lung cancer
Dr James Spicer - Guy's Hospital, London, UK
Round-up of the latest research on lung cancer ( Dr James Spicer - Guy's Hospital, London, UK )
9 Jun 2015
Lenvatinib increases progression free survival when used with everolimus in meta...
Dr James Larkin - Royal Marsden Hospital, London, UK
Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )
9 Jun 2015
Medically under-represented populations: Refining the calculation of accrual tar...
Dr Robert Comis - ECOG-ACRIN Cancer Research Group, Philadelphia, USA
Medically under-represented populations: Refining the calculation of accrual targets ( Dr Robert Comis - ECOG-ACRIN Cancer Research Group, Philadelphia, USA )
9 Jun 2015
Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer
Dr Simon Chowdhury - Guy's Hospital, London, UK
Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
9 Jun 2015
Screening to identify unsuitable candidates for ipilimumab in advanced melanoma
Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy
Screening to identify unsuitable candidates for ipilimumab in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )
9 Jun 2015
Nivolumab alone superior to ipilimumab alone in advanced melanoma
Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy
Nivolumab alone superior to ipilimumab alone in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )
8 Jun 2015
Extended adjuvant therapy for HER2-positive early breast cancer
Prof Arlene Chan - The Mount Hospital, Perth, Australia
Extended adjuvant therapy for HER2-positive early breast cancer ( Prof Arlene Chan - The Mount Hospital, Perth, Australia )
8 Jun 2015
New dexamethasone combination yields two-fold improvement in median PFS in multi...
Prof Meletios Dimopoulos - University of Athens, Athens, Greece
New dexamethasone combination yields two-fold improvement in median PFS in multiple myeloma ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )
5 Jun 2015
Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma
Prof Yilong Wu - President of the Chinese Society of Clinical Oncology
Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma ( Prof Yilong Wu - President of the Chinese Society of Clinical Oncology )
5 Jun 2015
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma
Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
5 Jun 2015
ASCO 2015: Latest developments in multiple myeloma
Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos
ASCO 2015: Latest developments in multiple myeloma ( Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos )
1 Jun 2015
Randomised trial of pembrolizumab versus standard treatment in patients with rec...
Dr Kevin Harrington - Institute of Cancer Research, London, UK
Randomised trial of pembrolizumab versus standard treatment in patients with recurrent or metastatic head and neck cancer ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )
1 Jun 2015
Adjuvant denosumab may preserve bone health in postmenopausal breast cancer pati...
Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
1 Jun 2015
ASCO 2015: Latest in chronic lymphocytic leukaemia
Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos
ASCO 2015: Latest in chronic lymphocytic leukaemia ( Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos )
1 Jun 2015
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma
Dr James Larkin - Royal Marsden Hospital, London, UK
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )
1 Jun 2015
Subgroup analysis of molecular markers in phase III study of high risk low-grade...
Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany
Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma ( Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany )
1 Jun 2015
Initial nivolumab-based treatment halts melanoma progression
Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA
Initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )
1 Jun 2015
Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyos...
Prof Gary Schwartz - Columbia University, New York, USA
Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma ( Prof Gary Schwartz - Columbia University, New York, USA )
1 Jun 2015
New intelligence network that supports efforts to improve quality of care and de...
Dr Allen Lichter, Chief Executive Officer, ASCO, USA
New intelligence network that supports efforts to improve quality of care and development of new medicines ( Dr Allen Lichter, Chief Executive Officer, ASCO, USA )
1 Jun 2015
Non-randomised clinical trial aims to describe the safety and efficacy of commer...
Dr Richard Schilsky - University of Chicago, Chicago, USA
Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs ( Dr Richard Schilsky - University of Chicago, Chicago, USA )
1 Jun 2015
Advanced DNA sequencing test used to match rare cancers
Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley
Advanced DNA sequencing test used to match rare cancers ( Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley )
1 Jun 2015
Developments in clinical trials and health information technology that will impr...
Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA
Developments in clinical trials and health information technology that will improve targeted therapies for patients ( Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA )
1 Jun 2015
Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chro...
Dr William Slayton - University of Florida, Gainsville, USA
Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL ( Dr William Slayton - University of Florida, Gainsville, USA )
1 Jun 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
31 May 2015
ASCO 2015: Latest developments in prostate cancer treatment
Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi
ASCO 2015: Latest developments in prostate cancer treatment ( Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi )
31 May 2015
Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preve...
Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA
Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer ( Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA )
31 May 2015
Next generation inhibitors help overcome problems of resistance in ALK positive ...
Dr Ross Camidge - University of Colorado, Denver, USA
Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer ( Dr Ross Camidge - University of Colorado, Denver, USA )
31 May 2015
Transarterial chemoembolization with or without sorafenib for intermediate-stage...
Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, C...
Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma ( Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, China )
31 May 2015
Letrozole vs observation for HR positive breast cancer
Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia
Letrozole vs observation for HR positive breast cancer ( Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia )
31 May 2015
Comment: Nivolumab-based treatment halts melanoma progression
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: Nivolumab-based treatment halts melanoma progression ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
31 May 2015
Risks of adjuvant whole brain radiation therapy outweigh benefits for patients w...
Dr Jan Buckner - Mayo Clinic, Rochester, USA
Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases ( Dr Jan Buckner - Mayo Clinic, Rochester, USA )
31 May 2015
Preventive neck lymph node surgery improves early oral cancer survival
Dr Anil D’Cruz - Tata Memorial Centre, Mumbai, India
Preventive neck lymph node surgery improves early oral cancer survival ( Dr Anil D’Cruz - Tata Memorial Centre, Mumbai, India )
31 May 2015
Preventive neck lymph node surgery improves early oral cancer survival
Dr Anil D’Cruz - Tata Memorial Centre, Mumbai, India
Preventive neck lymph node surgery improves early oral cancer survival ( Dr Anil D’Cruz - Tata Memorial Centre, Mumbai, India )
31 May 2015
Risks of adjuvant whole brain radiation therapy outweigh benefits for patients w...
Dr Jan Buckner - Mayo Clinic, Rochester, USA
Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases ( Dr Jan Buckner - Mayo Clinic, Rochester, USA )
31 May 2015
Improved care has extended lifespan of childhood cancer survivors since the 1970...
Dr Gregory Armstrong - St Jude Children’s Research Hospital, Mempis, USA
Improved care has extended lifespan of childhood cancer survivors since the 1970s ( Dr Gregory Armstrong - St Jude Children’s Research Hospital, Mempis, USA )
31 May 2015
Phase III study finds initial nivolumab-based treatment halts melanoma progressi...
Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA
Phase III study finds initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )
31 May 2015
Improved care has extended lifespan of childhood cancer survivors since the 1970...
Dr Gregory Armstrong - St Jude Children’s Research Hospital, Mempis, USA
Improved care has extended lifespan of childhood cancer survivors since the 1970s ( Dr Gregory Armstrong - St Jude Children’s Research Hospital, Mempis, USA )
31 May 2015
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphom...
Dr Merry-Jennifer Markham - University of Florida, Florida, USA
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis ( Dr Merry-Jennifer Markham - University of Florida, Florida, USA )
30 May 2015
Targeted drug daratumumab shows promise in heavily treatment-resistant multiple ...
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )
30 May 2015
Ibrutinib combination regimen shows substantial benefits in relapsed CLL
Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
Ibrutinib combination regimen shows substantial benefits in relapsed CLL ( Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Novel targeted drug palbociclib slows progression of hormone receptor-positive b...
Dr Nicholas Turner - The Institute of Cancer Research, London, UK
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )
30 May 2015
Anastrozole offers higher breast cancer-free survival rates than tamoxifen follo...
Prof Richard Margolese - The Jewish General Hospital, McGill University, Montrea...
Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )
30 May 2015
Extensive lymph node surgery may not be necessary for some patients with melanom...
Prof Claus Garbe - University of Tübingen, Tübingen, Germany
Extensive lymph node surgery may not be necessary for some patients with melanoma ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )
30 May 2015
Effective adjuvant chemotherapy for high-risk, localised prostate cancer
Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA
Effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA )
30 May 2015
Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofib...
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
30 May 2015
Novel targeted drug palbociclib slows progression of hormone receptor-positive b...
Dr Nicholas Turner - The Institute of Cancer Research, London, UK
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )
30 May 2015
Anastrazole offers higher breast cancer-free survival rates than tamoxifen follo...
Prof Richard Margolese - The Jewish General Hospital, McGill University, Montrea...
Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )
30 May 2015
Eribulin extends overall survival for patients with advanced liposarcoma and lei...
Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
30 May 2015
Extensive lymph node surgery may not be necessary for some patients with melanom...
Prof Claus Garbe - University of Tübingen, Tübingen, Germany.
Extensive lymph node surgery may not be necessary for some patients with melanoma ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany. )
30 May 2015
First effective adjuvant chemotherapy for high-risk, localised prostate cancer
Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.
First effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA. )
30 May 2015
Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibr...
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
30 May 2015
New ibrutinib combination regimen shows substantial benefits in relapsed chronic...
Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
30 May 2015
First-in-class targeted drug daratumumab shows promise in heavily treatment-resi...
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )
30 May 2015
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse predi...
Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction ( Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA )
29 May 2015
Pembrolizumab for head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab for head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Genomic marker predicts anti-PD-1 response in several cancers
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Genomic marker predicts anti-PD-1 response in several cancers ( Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
29 May 2015
Nivolumab extends survival for NSCLC
Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Nivolumab extends survival for NSCLC ( Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
29 May 2015
Promising results for nivolumab in advanced liver cancer
Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive ...
Promising results for nivolumab in advanced liver cancer ( Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA )
29 May 2015
Nivolumab extends survival for patients with the most common lung cancer
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Nivolumab extends survival for patients with the most common lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
29 May 2015
Pembrolizumab shows promising activity against head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab shows promising activity against head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Nivolumab shows highly promising activity in advanced liver cancer in early-stag...
Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive ...
Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial ( Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA )
29 May 2015
Genomic marker predicts anti-PD-1 response in several cancers
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Genomic marker predicts anti-PD-1 response in several cancers ( Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
29 May 2015